Published in J Biomed Sci on February 15, 2010
Matrix-metalloproteinases in head and neck carcinoma-cancer genome atlas analysis and fluorescence imaging in mice. Otolaryngol Head Neck Surg (2014) 0.85
Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer (2010) 0.84
Pathogenesis of apical periodontitis: a literature review. J Oral Maxillofac Res (2012) 0.80
Role of interstitial collagenase gene promoter polymorphism in the etiology of gastric cancer. Saudi J Gastroenterol (2014) 0.80
Cancer associated fibroblasts in hematological malignancies. Oncotarget (2015) 0.79
Functional characterization of the matrix metalloproteinase-1 cigarette smoke-responsive region and association with the lung health study. Respir Res (2012) 0.77
Preventive effects of Dendrobium candidum Wall ex Lindl. on the formation of lung metastases in BALB/c mice injected with 26-M3.1 colon carcinoma cells. Oncol Lett (2014) 0.77
The influence of matrix metalloproteinase-2, -9, and -12 promoter polymorphisms on Iranian patients with oesophageal squamous cell carcinoma. Contemp Oncol (Pozn) (2015) 0.76
Association between matrix metalloproteinase 1 -1607 1G>2G polymorphism and cancer risk: a meta-analysis including 19706 subjects. Int J Clin Exp Med (2014) 0.75
Association of Matrix Metalloproteinase-9 Gene -1562C/T Polymorphism with Essential Hypertension: A Systematic Review and Meta-Analysis Article. Iran J Public Health (2015) 0.75
Matrix metalloproteinases in exercise and obesity. Vasc Health Risk Manag (2016) 0.75
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22
Matrix metalloproteinases. J Biol Chem (1999) 12.08
Matrix metalloproteinases: a review. Crit Rev Oral Biol Med (1993) 9.03
Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 8.29
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol (2000) 4.98
Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J (1999) 4.85
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol (1997) 4.09
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res (1998) 3.77
Squamous cell carcinomas of the head and neck. BMJ (2002) 2.67
Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem (2000) 2.35
Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J (1993) 2.28
Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst (2001) 2.24
The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol (1992) 2.19
TIMPs as multifacial proteins. Crit Rev Oncol Hematol (2004) 2.18
Control of matrix metalloproteinase catalytic activity. Matrix Biol (2007) 2.18
Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol (2001) 2.14
Interstitial collagenases as markers of tumor progression. Clin Cancer Res (2000) 2.13
Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J (1989) 1.89
Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie (2005) 1.76
Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol (2000) 1.71
Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res (1992) 1.70
Matrix metalloproteinases and tumor progression. Adv Exp Med Biol (2003) 1.61
Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A (2006) 1.57
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol (2000) 1.57
Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol (2004) 1.52
Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol (2003) 1.50
Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. J Biol Chem (1983) 1.45
Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics (1994) 1.44
Prevalence of oral pre-malignant and malignant lesions at a tertiary level hospital in Allahabad, India. Asian Pac J Cancer Prev (2008) 1.35
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol (2004) 1.29
Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta (2009) 1.29
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res (2001) 1.19
Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation (2002) 1.16
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res (1999) 1.09
A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res (2002) 1.08
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population. Oral Oncol (2005) 1.08
A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer (1999) 1.08
Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol (2007) 1.08
Human macrophages synthesize and secrete a major 95,000-dalton gelatin-binding protein distinct from fibronectin. J Biol Chem (1982) 1.05
MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci (1999) 1.05
Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis (2000) 1.03
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res (2001) 1.02
Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett (2004) 1.00
Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep (2009) 0.99
Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin. FEBS Lett (1988) 0.98
Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim Biophys Acta (2002) 0.98
Type I collagen degradation by invasive oral squamous cell carcinoma. Oral Oncol (2000) 0.96
Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer (2009) 0.96
Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies. Mutagenesis (2009) 0.96
Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Anticancer Res (2007) 0.96
The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol (2005) 0.95
Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med (2004) 0.93
Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res (2004) 0.93
Matrix metalloproteinase-1 (-1607) 1G/2G and -9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas. Clin Chim Acta (2007) 0.91
Stromelysin-1 (MMP-3) is inducible in T lymphoma cells and accelerates the growth of lymphoid tumors in vivo. Biochem Biophys Res Commun (2004) 0.90
A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol (2007) 0.90
Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol Oncol (2005) 0.90
The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer (2007) 0.89
A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer. Auris Nasus Larynx (2008) 0.89
Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B. J Bone Miner Res (1996) 0.88
Cloning of the human tissue inhibitor of metalloproteinase-4 gene (TIMP4) and localization of the TIMP4 and Timp4 genes to human chromosome 3p25 and mouse chromosome 6, respectively. Genomics (1998) 0.88
Role of tobacco in the development of head and neck squamous cell carcinoma in an eastern Indian population. Asian Pac J Cancer Prev (2008) 0.87
The functional (-1171 5A-->6A) polymorphisms of matrix metalloproteinase 3 gene as a risk factor for oral submucous fibrosis among male areca users. J Oral Pathol Med (2006) 0.86
A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett (2003) 0.86
A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int (2007) 0.85
Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med (2007) 0.85
The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in Chinese. Int J Gynecol Cancer (2009) 0.84
Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer (2010) 0.84
MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer. Gynecol Oncol (2008) 0.84
Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol (2008) 0.84
Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol (2008) 0.84
Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res (1998) 0.83
Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs (1996) 0.81
Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet (2008) 0.80
Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. Cancer Res (1998) 0.77
Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. Clin Breast Cancer (2006) 0.76
Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res (2003) 5.72
A cross-sectional study evaluating chemiluminescence and autofluorescence in the detection of clinically innocuous precancerous and cancerous oral lesions. J Am Dent Assoc (2010) 2.46
Retracted Application of cytology and molecular biology in diagnosing premalignant or malignant oral lesions. Mol Cancer (2006) 2.09
Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U S A (2003) 1.87
Differential beta-adrenoceptor expression induced by nerve growth factor infusion into the canine right and left stellate ganglia. Heart Rhythm (2005) 1.58
Relationship between oxidative stress and embryotoxicity of hydrosalpingeal fluid. Hum Reprod (2002) 1.49
Low-affinity nerve growth factor receptor p75NTR immunoreactivity in the myocardium with sympathetic hyperinnervation. J Cardiovasc Electrophysiol (2004) 1.46
Effects of oral procyclidine administration on cognitive functions in healthy subjects: implications for schizophrenia. J Clin Psychopharmacol (2002) 1.39
Tobacco control in India: present scenario and challenges ahead. Asian Pac J Cancer Prev (2009) 1.37
Prevalence of oral pre-malignant and malignant lesions at a tertiary level hospital in Allahabad, India. Asian Pac J Cancer Prev (2008) 1.35
Correlation of histopathological diagnosis with habits and clinical findings in oral submucous fibrosis. Head Neck Oncol (2009) 1.33
Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer (2011) 1.33
Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J (2002) 1.32
Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta (2009) 1.29
Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. Int J Cancer (2006) 1.27
The effects of smoking on the developing lung: insights from a biologic model for lung development, homeostasis, and repair. Lung (2009) 1.25
Infection of human papillomaviruses in cancers of different human organ sites. Indian J Med Res (2009) 1.17
The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy (2002) 1.16
The use of an oral brush biopsy without computer-assisted analysis in the evaluation of oral lesions: a study of 94 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 1.16
Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation (2002) 1.16
The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study. Biol Psychiatry (2005) 1.14
Improving education in primary care: development of an online curriculum using the blended learning model. BMC Med Educ (2009) 1.12
Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. Mol Immunol (2010) 1.11
Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol (2002) 1.11
A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl) (2006) 1.10
Association of betel nut with carcinogenesis: revisit with a clinical perspective. PLoS One (2012) 1.10
Infraorbital cutaneous angiosarcoma: a diagnostic and therapeutic dilemma. Head Face Med (2008) 1.09
Role of human papillomavirus and its detection in potentially malignant and malignant head and neck lesions: updated review. Head Neck Oncol (2009) 1.07
Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther (2002) 1.03
Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. Int J Cancer (2010) 1.02
Prevalence of oral soft tissue lesions in Vidisha. BMC Res Notes (2010) 1.00
Utility of toluidine blue staining and brush biopsy in precancerous and cancerous oral lesions. Acta Cytol (2007) 0.98
Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol Cancer (2010) 0.98
Lipid profile in oral submucous fibrosis. Lipids Health Dis (2009) 0.98
Functional regulatory role of STAT3 in HPV16-mediated cervical carcinogenesis. PLoS One (2013) 0.97
Breast cancer and human papillomavirus infection: no evidence of HPV etiology of breast cancer in Indian women. BMC Cancer (2011) 0.97
Anticancer property of Bryophyllum pinnata (Lam.) Oken. leaf on human cervical cancer cells. BMC Complement Altern Med (2012) 0.96
Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigatus. J Immunol (2005) 0.95
p16 immunocytochemistry on cell blocks as an adjunct to cervical cytology: Potential reflex testing on specially prepared cell blocks from residual liquid-based cytology specimens. Cytojournal (2011) 0.95
Polymeric ocular hydrogels and ophthalmic inserts for controlled release of timolol maleate. J Pharm Bioallied Sci (2011) 0.94
Stimuli-sensitive hydrogels: a novel ophthalmic drug delivery system. Indian J Ophthalmol (2010) 0.94
Prevalence of viral (HPV, EBV, HSV) infections in oral submucous fibrosis and oral cancer from India. Acta Otolaryngol (2010) 0.94
Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis. Indian J Med Res (2010) 0.94
Protective roles of pulmonary surfactant proteins, SP-A and SP-D, against lung allergy and infection caused by Aspergillus fumigatus. Immunobiology (2002) 0.94
Iron, meat and health. Nutrients (2011) 0.92
Calcium wave signaling in cancer cells. Life Sci (2010) 0.91
Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro. Am J Physiol Heart Circ Physiol (2003) 0.91
Sex differences and individual differences in cognitive performance and their relationship to endogenous gonadal hormones and gonadotropins. Behav Neurosci (2005) 0.91
Silver nanoparticles synthesized by pulsed laser ablation: as a potent antibacterial agent for human enteropathogenic gram-positive and gram-negative bacterial strains. Appl Biochem Biotechnol (2014) 0.90
Morphometric analysis in potentially malignant head and neck lesions: oral submucous fibrosis. Asian Pac J Cancer Prev (2010) 0.90
Comparative study between the Hybrid Capture II test and PCR based assay for the detection of human papillomavirus DNA in oral submucous fibrosis and oral squamous cell carcinoma. Virol J (2010) 0.89
Efficacy of a fish protein hydrolysate in malnourished children. Indian J Clin Biochem (2011) 0.89
Autofluorescence--an important ancillary technique for the detection of Mycobacterium tuberculosis: revisited. Diagn Cytopathol (2012) 0.89
Identification of salivary mucin MUC7 binding proteins from Streptococcus gordonii. BMC Microbiol (2009) 0.88
Surfactant proteins SP-A and SP-D in human health and disease. Arch Immunol Ther Exp (Warsz) (2005) 0.88
Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer (2010) 0.88
Centchroman mediated apoptosis involves cross-talk between extrinsic/intrinsic pathways and oxidative regulation. Life Sci (2010) 0.87
Defining binding efficiency and specificity of auxins for SCF(TIR1/AFB)-Aux/IAA co-receptor complex formation. ACS Chem Biol (2013) 0.87
Tobacco use by Indian medical students and the need for comprehensive intervention strategies. Asian Pac J Cancer Prev (2010) 0.87
Deregulation of microRNAs Let-7a and miR-21 mediate aberrant STAT3 signaling during human papillomavirus-induced cervical carcinogenesis: role of E6 oncoprotein. BMC Cancer (2014) 0.87
DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog (2003) 0.86
Polyphosphate deficiency in Mycobacterium tuberculosis is associated with enhanced drug susceptibility and impaired growth in guinea pigs. J Bacteriol (2013) 0.86
Transcription factor AP-1 in esophageal squamous cell carcinoma: alterations in activity and expression during human Papillomavirus infection. BMC Cancer (2009) 0.86
The positive inotropic and calcium-mobilizing effects of growth hormone-releasing peptides on rat heart. Endocrinology (2003) 0.84
A gp63 based vaccine candidate against Visceral Leishmaniasis. Bioinformation (2011) 0.84
Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer (2010) 0.84
Application of a multiplex PCR to cervical cells collected by a paper smear for the simultaneous detection of all mucosal human papillomaviruses (HPVs) and typing of high-risk HPV types 16 and 18. J Med Microbiol (2010) 0.84
The buccal minor salivary glands as starting point for a metastasizing adenocarcinoma--report of a case. Head Face Med (2008) 0.84
Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: association with clinicopathological parameters. Anticancer Res (2005) 0.83
Serial scrape smear cytology of radiation response in normal and malignant cells of oral cavity. Indian J Pathol Microbiol (2004) 0.83
Cognitive impairment but preservation of sexual dimorphism in cognitive abilities in chronic schizophrenia. Psychiatry Res (2006) 0.83
Preparation and in vitro evaluation of folate-receptor-targeted SPION-polymer micelle hybrids for MRI contrast enhancement in cancer imaging. Nanotechnology (2012) 0.83
Correlation of addictive factors, human papilloma virus infection and histopathology of oral submucous fibrosis. J Oral Pathol Med (2010) 0.83
Fine-needle aspiration cytology of primitive neuroectodermal tumor of the urinary bladder: a case report. Diagn Cytopathol (2010) 0.83
Disruption of learned irrelevance in acute schizophrenia in a novel continuous within-subject paradigm suitable for fMRI. Behav Brain Res (2005) 0.83
Multiple intraductal papillomas of breast clinically masquerading as malignancy. Indian J Pathol Microbiol (2010) 0.82
Changing pattern of oral cavity lesions and personal habits over a decade: hospital based record analysis from allahabad. Indian J Community Med (2009) 0.82
Radiation-related cytological changes in oral malignant cells. Indian J Pathol Microbiol (2004) 0.82
GSTM1 and GSTT1 polymorphism and susceptibility to esophageal cancer in high- and low-risk regions of India. Tumour Biol (2013) 0.81
HIV seroprevalence in patients with tuberculosis in Allahabad, North India. Indian J Pathol Microbiol (2006) 0.81
Pleomorphic lipoma of the tonsillar fossa--a case report. Indian J Pathol Microbiol (2003) 0.81
Extramedullary blast crisis in chronic myeloid leukemia--a case report. Indian J Pathol Microbiol (2005) 0.81
Does self-perceived mood predict more variance in cognitive performance than clinician-rated symptoms in schizophrenia? Schizophr Bull (2006) 0.81
Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer. BMC Cancer (2009) 0.80
Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer (2010) 0.80
Medication adherence in patients with epilepsy after a single neurologist visit in rural India. Epilepsy Behav (2013) 0.80
Utility of plasma tumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma. Biomarkers (2010) 0.80